Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment-Reference-Cited by-同舟云学术

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment

Published:2024-06 Issue:2 Volume:24 Page:341-352
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Ferri Nicola^ORCID,De Martin Sara,Stuart James,Traversa Sergio,Mattarei Andrea,Comai Stefano,Folli Franco,Pappagallo Marco,Guidetti Clotilde,Inturrisi Charles E.,Manfredi Paolo L.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40268-024-00477-3.pdf

Reference26 articles.

1. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 1997;223(1):5–8.

2. Bettini E, Stahl SM, De Martin S, Mattarei A, Sgrignani J, Carignani C, et al. Pharmacological comparative characterization of REL-1017 (Esmethadone-HCl) and other NMDAR channel blockers in human heterodimeric N-methyl-d-aspartate receptors. Pharmaceuticals (Basel). 2022;15(8):997.

3. Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, et al. REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial. Am J Psychiatry. 2022;179(2):122–31.

4. Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S, et al. Esmethadone-HCl (REL-1017): a promising rapid antidepressant. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1463–76.

5. Amidfar M, Woelfer M, Reus GZ, Quevedo J, Walter M, Kim YK. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: evidence from translational research. Prog Neuropsychopharmacol Biol Psychiatry. 2019;30(94): 109668.